R1 RCM has received a noncompliance notice from Nasdaq’s Listing Qualifications Department resulting from R1’s delay in filing its quarterly report on Form 10-Q for the third quarter of 2023. Nasdaq’s ...

MURRAY, Utah, June 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial ...

Update 4:30pm: Updates shares, adds comment from R1 RCM holder. R1 RCM (NASDAQ:RCM) jumped 25% after New Mountain offered to buy the company for $13.75 a share in a cash. New Mountain also requested ...

R1 RCM has received an investment from venture capital firm Khosla Ventures to further its push into AI-powered healthcare revenue cycle transformation. Khosla Ventures is a leading backer of AI ...

New Mountain Capital is offering to buy out other investors in revenue cycle management giant R1 RCM for $13.75 a share in cash. The private equity firm’s offer represents a 24% premium to R1’s ...

In a report released today, Daniel Grosslight from Citi downgraded R1 RCM (RCM – Research Report) to a Hold, with a price target of $14.30. Daniel Grosslight has given his Hold rating due to a ...

MURRAY, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of ...

Voss Capital, LLC an investment management company, released its first-quarter 2024 investor letter. A copy of the letter can be downloaded here. Voss Capital’s funds, Voss Value Fund, LP, and the ...

Fintel reports that on February 28, 2024, Barclays downgraded their outlook for R1 RCM (NasdaqGS:RCM) from Overweight to Equal-Weight. As of February 24, 2024, the average one-year price target for R1 ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would ...

(Reuters) -R1 RCM said on Thursday private-equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice (CD&R) would acquire the healthcare technology company in a deal that values it at $8.9 ...